scispace - formally typeset
Open AccessJournal ArticleDOI

Guideline-Concordant Antipsychotic Use and Mortality in Schizophrenia

Reads0
Chats0
TLDR
Adherence to PORT pharmacological guidelines is associated with reduced mortality among patients with schizophrenia and adoption of outcomes monitoring systems and innovative service delivery programs to improve adherence should be considered.
Abstract
Objective: To determine if care concordant with 2009 Schizophrenia Patient Outcomes Research Team (PORT) pharmacological recommendations for schizophrenia is associated with decreased mortality. Methods: We conducted a retrospective cohort study of adult Maryland Medicaid beneficiaries with schizophrenia and any antipsychotic use from 1994 to 2004 (N = 2132). We used Medicaid pharmacy data to measure annual and average antipsychotic continuity, to calculate chlorpromazine (CPZ) dosing equivalents, and to examine anti-Parkinson medication use. Cox proportional hazards regression models were used to examine the relationship between antipsychotic continuity, antipsychotic dosing, and anti-Parkinson medication use and mortality. Results: Annual antipsychotic continuity was associated with decreased mortality. Among patients with annual continuity greater than or equal to 90%, the hazard ratio [HR] for mortality was 0.75 (95% confidence interval [CI] 0.57–0.99) compared with patients with annual medication possession ratios (MPRs) of less than 10%. The HRs for mortality associated with continuous annual and average antipsychotic continuity were 0.75 (95% CI 0.58–0.98) and 0.84 (95% CI 0.58–1.21), respectively. Among users of first-generation antipsychotics, doses greater than or equal to 1500 CPZ dosing equivalents were associated with increased risk of mortality (HR 1.88, 95% CI 1.10–3.21), and use of anti-Parkinson medication was associated with decreased risk of mortality (HR 0.72, 95% CI 0.55–0.95). Mental health visits were also associated with decreased mortality (HR 0.96, 95% CI 0.93–0.98). Conclusions: Adherence to PORT pharmacological guidelines is associated with reduced mortality among patients with schizophrenia. Adoption of outcomes monitoring systems and innovative service delivery programs to improve adherence to the PORT guidelines should be considered.

read more

Citations
More filters
Journal ArticleDOI

Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study

TL;DR: Moderate and high-dose antipsychotic and antidepressant use were associated with 15%-40% lower overall mortality, whereas chronic high- dose use of benzodiazepines was associated with up to a 70% higher risk of death compared with no exposure.
Journal ArticleDOI

Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010

TL;DR: Numbers of excess deaths and attributable deaths clearly demonstrate the high degree of mortality associated with these disorders and the life expectancy gap between persons with MNSDs and the general population is high and should be a focus for health systems reform.
Journal ArticleDOI

The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders

TL;DR: A strong association between being prescribed clozapine and lower mortality was identified which persisted after controlling for a broad range of potential confounders including clinical monitoring and markers of disease severity and after restricting the sample to those with a diagnosis of schizophrenia or those taking antipsychotics.
References
More filters
Journal ArticleDOI

Comorbidity measures for use with administrative data.

TL;DR: The present method addresses some of the limitations of previous measures and produces an expanded set of comorbidities that easily is applied without further refinement to administrative data for a wide range of diseases.
Journal ArticleDOI

Practice guideline for the treatment of patients with schizophrenia

Journal ArticleDOI

A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

TL;DR: In light of the potential for second-generation antipsychotic medications to further adversely influence mortality rates in the decades to come, optimizing the general health of people with schizophrenia warrants urgent attention.
Related Papers (5)